1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
Delayed Nasdaq Stockholm  -  11:29 2022-07-01 am EDT
32.10 SEK   -1.53%
06/30Biovica's CFO will leave in December 2022
AQ
06/30Biovica International AB Announces Resignation of Cecilia Driving as deputy CEO, Effective December 31, 2022
CI
06/30Biovica International AB Announces Resignation of Cecilia Driving as CFO, Effective December 31, 2022
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
34(c) 33.2(c) 32(c) 32.6(c) 32.1(c) Last
23 237 6 991 6 011 5 455 19 157 Volume
-3.95% -2.35% -3.61% +1.88% -1.53% Change
More quotes
Estimated financial data (e)
Sales 2022 1,00 M 0,10 M 0,10 M
Net income 2022 -37,1 M -3,59 M -3,59 M
Net cash position 2022 277 M 26,8 M 26,8 M
P/E ratio 2022 -21,7x
Yield 2022 -
Sales 2023 8,00 M 0,77 M 0,77 M
Net income 2023 -66,0 M -6,38 M -6,38 M
Net cash position 2023 20,0 M 1,93 M 1,93 M
P/E ratio 2023 -13,8x
Yield 2023 -
Capitalization 914 M 88,4 M 88,4 M
EV / Sales 2022 638x
EV / Sales 2023 112x
Nbr of Employees 28
Free-Float 42,9%
More Financials
Company
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates... 
More about the company
Ratings of Biovica International AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about BIOVICA INTERNATIONAL AB (PUBL)
06/30Biovica's CFO will leave in December 2022
AQ
06/30Biovica International AB Announces Resignation of Cecilia Driving as deputy CEO, Effect..
CI
06/30Biovica International AB Announces Resignation of Cecilia Driving as CFO, Effective Dec..
CI
06/30Biovica International AB – Annual report for the financial year 2021/2022 publish..
AQ
06/16TRANSCRIPT : Biovica International AB, 2022 Earnings Call, Jun 16, 2022
CI
06/16Year-end Report 2021/2022 - Preparations for the upcoming US launch
AQ
06/16Biovica International AB Reports Earnings Results for the Fourth Quarter Ended April 30..
CI
06/16Biovica International AB Reports Earnings Results for the Full Year Ended April 30, 202..
CI
06/13DiviTum«TKa predicts clinical outcome of patients in BioItaLEE study
AQ
06/13Biovica International Announces DiviTumTKa Predicts Clinical Outcome of Patients in Bio..
CI
05/17TRANSCRIPT : Biovica International AB - Analyst/Investor Day
CI
05/09Biovica's DiviTum«TKa at ASCO
AQ
04/28Biovica completes 510(k) submission for DiviTum«TKa to the FDA
AQ
04/28Biovica completes 510(k) submission for DiviTum«TKa to the FDA
CI
04/28Biovica Capital Markets Day invitation May 17, 2022
AQ
More news
News in other languages on BIOVICA INTERNATIONAL AB (PUBL)
06/30Biovica International AB (Publ) annonce la démission de Cecilia Driving en tant que PDG..
06/16Biovica International AB (publ) annonce ses résultats financiers pour le quatrième trim..
06/16Biovica International AB (publ) publie ses résultats financiers pour l'exercice complet..
06/13Biovica International annonce que DiviTumTKa prédit le résultat clinique des patients d..
04/28Biovica complète la soumission 510(k) du DiviTum«TKa à la FDA
More news
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 32,10
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving Chief Financial Officer, Deputy CEO & Executive VP
Lars Erik Holmqvist Chairman
Otti Bengtsson Gref Vice President-Research & Development
Tomas Andersson Vice President-Operations
Sector and Competitors